Strengthening Drug Discovery and Development with Original New Drugs as a Growth Driver
First written in FY2017-Q1. 22 of 30 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2019: 1 of 10 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「Kyorin Pharmaceutical Co., Ltd. has designated pain, autoimmune diseases and neuromuscular diseases as priority areas and is seeking to strengthen its ability to discover new drugs by transforming its research structure around these areas. Under this structure, in addition to further strengthening its core technology of small-molecule drug discovery, the company is actively acquiring external assets and expanding into new modalities.」
The company has focused drug-discovery efforts on pain, autoimmune diseases and neuromuscular diseases, organizing its initiatives around a research structure focused on these areas, the acquisition of external assets and expansion into new modalities. - FY2026-H1RestatedAnnual report
「In addition to further strengthening its core technology of small-molecule drug discovery, the company is working to strengthen its drug-discovery platform by expanding the modalities it researches and leveraging external technologies, while pursuing drug-discovery innovation that creates new clinical value through combination with disease research.」
In addition to strengthening small-molecule drug discovery, the company continues to pursue drug-discovery innovation by expanding its research modalities, leveraging external technologies and combining them with disease research. - FY2025-H1RestatedAnnual report
「We are strengthening our drug discovery platform by utilizing external technologies, including nucleic acid drug discovery as a new modality in addition to the small-molecule drug discovery on which we have focused to date, and are pursuing drug discovery innovation to create high-value new drugs by combining these efforts with disease research.」
In addition to small-molecule drug discovery, the company continues to strengthen its drug-discovery platform by combining external technologies, including nucleic-acid drug discovery, with disease research. - FY2024AdvancedAnnual report
「We established a Research Planning Department and a Basic Research Institute at the Watarase Drug Discovery Center to access external drug discovery seeds and introduce external technologies.」
Efforts to strengthen drug discovery through the creation of original new drugs and the use of external technologies progressed to the establishment of a Research Planning Department and a Basic Research Institute at the Watarase Drug Discovery Center. - FY2024-Q3RestatedAnnual report
「We are strengthening our drug discovery platform by actively promoting the use of nucleic acid drug discovery and innovative external technologies as new modalities in addition to the small-molecule drug discovery on which we have focused to date, and are pursuing drug discovery innovation to create high-value new drugs by combining these efforts with disease research.」
It continues to pursue drug discovery innovation combining small-molecule drug discovery with nucleic acid drug discovery, external technologies and disease research. - FY2024-Q2RestatedAnnual report
「We are strengthening our drug discovery platform by actively expanding the use of nucleic acid drug discovery and innovative external technologies as new modalities in addition to the small-molecule drug discovery on which we have focused to date, and are pursuing drug discovery innovation to create high-value new drugs by combining these efforts with disease research.」
It continues to strengthen its drug discovery platform by combining small-molecule drug discovery with nucleic acid drug discovery, external technologies and disease research. - FY2024-Q1ReframedAnnual report
「We are strengthening our drug discovery platform by actively expanding the use of nucleic acid drug discovery and innovative external technologies as new modalities in addition to the small-molecule drug discovery on which we have focused to date, and are pursuing drug discovery innovation to create high-value new drugs by combining these efforts with disease research.」
It is expanding the means of creating original new drugs from conventional small-molecule drug discovery to drug discovery innovation utilizing nucleic acid drug discovery and innovative external technologies. - FY2023-Q1RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. worked to activate its drug discovery platform by adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids.」
It continues to pursue in-house drug discovery, open innovation with external organizations, activation of its drug discovery platform, and the application and development of new technologies. - FY2022-Q3RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. worked to activate its drug discovery platform by adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids and peptides.」
It continues to pursue in-house drug discovery, open innovation with external organizations, activation of its drug discovery platform, and the application and development of new technologies. - FY2022-Q2RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. worked to activate its drug discovery platform by adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids and peptides.」
It continues to pursue in-house drug discovery, open innovation with external organizations, activation of its drug discovery platform, and the application and development of new technologies. - FY2022-Q1SoftenedAnnual report
「We actively explored and considered the introduction of external drug discovery programs and developed initiatives aimed at first-in-class drug discovery.」
Regarding external drug discovery programs, the wording has changed from “explore and introduce” to “consider exploring and introducing.” - FY2021-Q3RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. aims to become a company recognized worldwide for creating innovative new drugs. It is working to activate its drug discovery platform through open innovation with domestic and overseas pharmaceutical companies, academia and venture companies in addition to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids and peptides.」
It continues to pursue in-house drug discovery, open innovation with external organizations, activation of its drug discovery platform, and the application and development of new technologies. - FY2021-Q2RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. aims to become a company recognized worldwide for creating innovative new drugs. It is working to activate its drug discovery platform through open innovation with domestic and overseas pharmaceutical companies, academia and venture companies in addition to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids and peptides.」
It continues to pursue in-house drug discovery, open innovation with external organizations, activation of its drug discovery platform, and the application and development of new technologies. - FY2021-Q1RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. aims to become a company recognized worldwide for creating innovative new drugs. It is working to activate its drug discovery platform through open innovation with domestic and overseas pharmaceutical companies, academia and venture companies in addition to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids and peptides.」
It continues to pursue in-house drug discovery, open innovation with external organizations, activation of its drug discovery platform, and the application and development of new technologies, with the aim of creating innovative new drugs. - FY2020Cited as achievedAnnual report
「Alongside establishing a drug discovery structure, we selected and concentrated our drug discovery programs and pursued multilayered program development in fibrosis and kinase research. We also actively explored and introduced external drug discovery programs, including the in-licensing of a treatment for interstitial lung disease, making steady progress toward first-in-class drug discovery.」
It cites the establishment of a drug discovery structure in Stage 2, the selection and concentration of research programs, multilayered development, and the introduction of external programs as past initiatives and achievements. - FY2020-Q3RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd., based on the recognition that creating original new drugs is the true engine of growth, is working to further activate its existing drug discovery platform through open innovation with domestic and overseas pharmaceutical companies, academia and venture companies in addition to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids, peptides and gene therapy.」
It continues to pursue in-house drug discovery, open innovation with external organizations, and the use of new technologies such as nucleic acids, peptides and gene therapy. - FY2020-Q1RestatedAnnual report
「Based on the recognition that creating original new drugs is the true engine of growth, we worked to further activate our existing drug discovery platform through open innovation with domestic and overseas pharmaceutical companies, academia and venture companies in addition to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids, peptides and gene therapy.」
It continues to combine in-house drug discovery with open innovation involving external organizations, activate its drug discovery platform, and utilize new technologies such as nucleic acids, peptides and gene therapy. - FY2019RestatedAnnual report
「Based on the recognition that creating original new drugs is the true engine of growth and leads to sustainable growth, we are adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery conducted through collaboration between the Watarase Drug Discovery Center and ActivX,」
It continues to pursue a policy of adding open innovation with external organizations to in-house drug discovery and making original new drugs an engine of sustainable growth. - FY2019-Q3RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. is working to further strengthen its drug discovery platform by adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery conducted through collaboration between the Watarase Drug Discovery Center and ActivX, based on the recognition that creating original new drugs is the true engine of growth and leads to sustainable growth.」
It continues to pursue a direction of strengthening its drug discovery platform by adding open innovation with external organizations to in-house drug discovery conducted by the Watarase Drug Discovery Center and ActivX. - FY2019-Q2RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. is working to further strengthen its drug discovery platform by adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery conducted through collaboration between the Watarase Drug Discovery Center and ActivX, based on the recognition that creating original new drugs is the true engine of growth and leads to sustainable growth.」
It continues to pursue a direction of strengthening its drug discovery platform by adding open innovation with external organizations to in-house drug discovery conducted by the Watarase Drug Discovery Center and ActivX. - FY2019-Q1RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. is working to strengthen its drug discovery capabilities by adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to its in-house drug discovery, based on the recognition that creating original new drugs is the true engine of growth and leads to sustainable growth.」
It continues to pursue a policy of strengthening drug discovery capabilities by combining in-house drug discovery with open innovation involving external companies, academia and venture companies. - FY2018RestatedAnnual report
「Based on the recognition that creating original new drugs is the true engine of growth and leads to sustainable growth, we are working to strengthen our drug discovery capabilities through our own basic research technologies and open innovation.」
It continues to view strengthening drug discovery capabilities through in-house drug discovery and open innovation as an engine of sustainable growth. - FY2018-Q3RestatedAnnual report
「At Kyorin Pharmaceutical Co., Ltd., based on the recognition that creating original new drugs is the true engine of growth, and that strengthening the new drug business will enhance the raison d'être of our group and lead to sustainable growth, we are advancing in-house drug discovery and the development of in-licensed products,」
It continues to view strengthening the new drug business through in-house drug discovery and the development of in-licensed products as an engine of sustainable growth. - FY2018-Q2RestatedAnnual report
「Based on the recognition that creating original new drugs is the true engine of growth, and that strengthening the new drug business will enhance the raison d'être of our group and lead to sustainable growth, we are advancing in-house drug discovery and the development of in-licensed products,」
It continues to view strengthening the new drug business through in-house drug discovery and the development of in-licensed products as an engine of sustainable growth. - FY2017RestatedAnnual report
「Based on the recognition that creating original new drugs is the true engine of growth, and that strengthening the new drug business will enhance the raison d'être of our group and lead to sustainable growth, we are advancing in-house drug discovery and the development of in-licensed products,」
It continues to view strengthening the new drug business through in-house drug discovery and the development of in-licensed products as an engine of sustainable growth. - FY2017-Q3RestatedAnnual report
「At Kyorin Pharmaceutical Co., Ltd., based on the recognition that creating original new drugs is the true engine of growth, and that strengthening the new drug business will enhance the raison d'être of our group and lead to sustainable growth, we are advancing in-house drug discovery and the development of in-licensed products,」
It continues to view strengthening the new drug business through in-house drug discovery and the development of in-licensed products as an engine of sustainable growth. - FY2017-Q2RestatedAnnual report
「Based on the recognition that creating original new drugs is the true engine of growth, and that strengthening the new drug business will enhance the raison d'être of our group and lead to sustainable growth, we are advancing in-house drug discovery and the development of in-licensed products,」
It continues to view strengthening the new drug business through in-house drug discovery and the development of in-licensed products as an engine of sustainable growth. - FY2017-Q1First statedAnnual report
「Based on the recognition that creating original new drugs is the true engine of growth, and that strengthening the new drug business enhances the Group’s raison d’être and supports sustainable growth, we are advancing in-house drug discovery and the development of in-licensed products.」
The Group intends to strengthen its new drug business through in-house drug discovery and development of in-licensed products, thereby supporting sustainable growth.